Design of Reach:Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD

Authors :: Tawil, R.
Han, J.
Wang, L.
Vissing, J.
van Engelen, B.
Statland, J.
Mellion, M.
Shoskes, J.
Morabito, C.
Jiang, J.
Webster, J.
Tawil, R.
Han, J.
Wang, L.
Vissing, J.
van Engelen, B.
Statland, J.
Mellion, M.
Shoskes, J.
Morabito, C.
Jiang, J.
Webster, J.
Source :: Tawil , R , Han , J , Wang , L , Vissing , J , van Engelen , B , Statland , J , Mellion , M , Shoskes , J , Morabito , C , Jiang , J & Webster , J 2022 , ' Design of Reach : Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD ' , Neuromuscular Disorders , vol. 32 , no. Supplement 1 , P.136 , pp. S104-S104 .
Publication Year :: 2022

Database :: OAIster
Journal :: Tawil , R , Han , J , Wang , L , Vissing , J , van Engelen , B , Statland , J , Mellion , M , Shoskes , J , Morabito , C , Jiang , J & Webster , J 2022 , ' Design of Reach : Phase 3 randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in FSHD ' , Neuromuscular Disorders , vol. 32 , no. Supplement 1 , P.136 , pp. S104-S104 .
Notes :: English
Publication Type :: Electronic Resource
Accession number :: edsoai.on1382520177
Document Type :: Electronic Resource

Tools